Using two different COVID-19 vaccine brands to complete vaccine doses was “not recommended”, according to Duque.
Health Secretary Francisco Duque III on Friday said that using two different COVID-19 vaccine brands to complete the needed two vaccine doses was not recommended.
In response to Senate President Vicente Sotto III’s query, Duque told the Senate Committee of the Whole that if an adverse event following vaccination did happen or an adverse event of special interest, they’re going to struggle to identify which of these two different COVID-19 vaccine brands must have caused it.
Philippine Medical Association’s Adhoc Committee on Vaccination chairperson Dr. Lulu Bravo also advised against such practice as this was “not recommended”.
According to Dr. Bravo, no company would be willing to do a study on that kind of process as most of the results that they would get, if this would be done, won’t really be based on standard procedures.
READ ALSO: Pfizer Commits To Give Supplies Of COVID-19 Vaccine To PH “As Quickly As Possible”
Only the COVID-19 vaccine jointly developed by Pfizer and BioNTech had secured an emergency use authorization (EUA) from the Philippine Food and Drug Administration (FDA) so far.
With this, Pfizer had committed to give the needed supplies of COVID-19 vaccine for the upcoming inoculation program of the Philippine government “as quickly as possible”.
Meanwhile, the result of the EUA application of AstraZeneca was expected to be within the month as well.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via the official Facebook page and YouTube channel.
